# Use of Activated Recombinant Human Factor VII in Cardiac Surgery

> **NCT00154427** · PHASE2 · TERMINATED · sponsor: **Novo Nordisk A/S** · enrollment: 172 (actual)

## Conditions studied

- Acquired Bleeding Disorder
- Cardiac Surgery Requiring Cardiopulmonary Bypass

## Interventions

- **DRUG:** activated recombinant human factor VII

## Key facts

- **NCT ID:** NCT00154427
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2004-08
- **Primary completion:** 2007-11
- **Final completion:** 2007-11
- **Target enrollment:** 172 (ACTUAL)
- **Why stopped:** Trial terminated after recruiting 172 patients but without proceeding to the highest dosing cohort as this no longer reflects common clinical practice
- **Last updated:** 2017-01-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00154427

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00154427, "Use of Activated Recombinant Human Factor VII in Cardiac Surgery". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT00154427. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*